Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human. [electronic resource]
- Drug metabolism and disposition: the biological fate of chemicals Sep 2012
- 1785-96 p. digital
Publication Type: Journal Article
1521-009X
10.1124/dmd.112.046052 doi
ATP Binding Cassette Transporter, Subfamily B--deficiency ATP Binding Cassette Transporter, Subfamily G, Member 2 ATP-Binding Cassette Transporters--deficiency Administration, Oral Animals Antineoplastic Agents--administration & dosage Area Under Curve Biological Availability Biotransformation Brain--metabolism Breast Neoplasms--drug therapy Bridged Bicyclo Compounds, Heterocyclic--administration & dosage Cell Membrane Permeability Dogs Drug Dosage Calculations Female Half-Life Hepatocytes--metabolism Humans Injections, Intravenous Intestinal Absorption Liver--metabolism MCF-7 Cells Macaca fascicularis Madin Darby Canine Kidney Cells Male Metabolic Clearance Rate Mice Mice, Knockout Models, Biological Phosphatidylinositol 3-Kinase--metabolism Phosphoinositide-3 Kinase Inhibitors Protein Binding Protein Kinase Inhibitors--administration & dosage Pyrimidines--administration & dosage Rats Rats, Sprague-Dawley Receptor, ErbB-2--genetics Species Specificity TOR Serine-Threonine Kinases--antagonists & inhibitors Tissue Distribution Transfection Xenograft Model Antitumor Assays ATP-Binding Cassette Sub-Family B Member 4